Venera Kuci Emruli1, Leena Liljedahl1, Ulrika Axelsson1, Corinna Richter1, Lisa Theorin1, Anders Bjartell2,3, Hans Lilja3,4,5, Jenny Donovan6, David Neal5, Freddie C Hamdy5, Carl A K Borrebaeck1. 1. Department of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden. 2. Department of Urology, Skåne University Hospital, Malmö, Sweden. 3. Department of Translational Medicine, Lund University, Malmö, Sweden. 4. Department of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 5. The Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. 6. Bristol Medical School, University of Bristol, Bristol, UK.
Abstract
PURPOSE: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. EXPERIMENTAL DESIGN: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. RESULTS: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. CONCLUSIONS AND CLINICAL RELEVANCE: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
PURPOSE: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. EXPERIMENTAL DESIGN: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. RESULTS: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. CONCLUSIONS AND CLINICAL RELEVANCE: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
Authors: W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick Journal: JAMA Date: 1998-05-20 Impact factor: 56.272
Authors: Kathleen C Day; Guadalupe Lorenzatti Hiles; Molly Kozminsky; Scott J Dawsey; Alyssa Paul; Luke J Broses; Rajal Shah; Lakshmi P Kunja; Christopher Hall; Nallasivam Palanisamy; Stephanie Daignault-Newton; Layla El-Sawy; Steven James Wilson; Andrew Chou; Kathleen Woods Ignatoski; Evan Keller; Dafydd Thomas; Sunitha Nagrath; Todd Morgan; Mark L Day Journal: Cancer Res Date: 2016-10-28 Impact factor: 12.701
Authors: Janielle P Maynard; Onur Ertunc; Ibrahim Kulac; Javier A Baena-Del Valle; Angelo M De Marzo; Karen S Sfanos Journal: Mol Cancer Res Date: 2019-10-11 Impact factor: 5.852
Authors: Anders Carlsson; Christer Wingren; Johan Ingvarsson; Peter Ellmark; Bo Baldertorp; Mårten Fernö; Håkan Olsson; Carl A K Borrebaeck Journal: Eur J Cancer Date: 2008-01-02 Impact factor: 9.162
Authors: Henrik Grönberg; Jan Adolfsson; Markus Aly; Tobias Nordström; Peter Wiklund; Yvonne Brandberg; James Thompson; Fredrik Wiklund; Johan Lindberg; Mark Clements; Lars Egevad; Martin Eklund Journal: Lancet Oncol Date: 2015-11-10 Impact factor: 41.316